Kenya has received an initial shipment of 21,000 starter doses of Lenacapavir, a long-acting injectable HIV pre-exposure prophylaxis (PrEP), marking a significant milestone in the country’s fight against new infections.
Landmark Step in HIV Prevention
The consignment was received by Director General for Health Dr. Patrick Amoth, who described Kenya’s inclusion among the first East African countries to roll out the drug as a testament to its readiness to adopt innovative, people-centred HIV prevention strategies.
Lenacapavir is a long-acting antiretroviral drug designed for adults with multidrug-resistant HIV. Health officials emphasized that it is not a vaccine but a preventive medicine administered twice a year, with patients expected to access it at approximately Ksh. 7,800 annually.
Global and Local Approvals
The drug was approved by the U.S. Food and Drug Administration (FDA) in June 2025 and later endorsed by the World Health Organisation (WHO). In January 2026, Kenya’s Pharmacy and Poisons Board (PPB) completed a scientific review and recommended its registration for national use.
Support and Rollout Plan
The consignment was delivered with support from the Global Fund, with an additional 12,000 continuation doses expected by April. The United States has also committed 25,000 doses to strengthen early implementation.
Through the National AIDS and STI Control Programme (NASCOP), the Ministry of Health will oversee a phased rollout beginning in March 2026 across 15 high-burden counties. The first phase will cover:
- Mombasa
- Kilifi
- Machakos
- Kakamega
- Siaya
- Kisumu
- Migori
- Homabay
Two additional phases will expand coverage nationwide.
Addressing Kenya’s HIV Burden
Kenya continues to face a significant HIV challenge, with 41% of new infections occurring among young people. The introduction of Lenacapavir offers expanded prevention options, complementing existing strategies and reinforcing the country’s commitment to reducing transmission rates.
Conclusion
The rollout of Lenacapavir represents a transformative step in HIV prevention in Kenya. By combining international support, scientific innovation, and targeted implementation, the country is positioning itself at the forefront of efforts to curb new infections and protect vulnerable populations.
